P0968 - Risk of Myocarditis and Pericarditis in Patients With Inflammatory Bowel Disease: A Multi-Network Study

Jenny Jan, MD¹, Jacques Halabi, MD², Elleson G. Harper, BS², Jaime A. Perez, PhD³, Kanwal Bains, MD⁴, Preetika Sinh, MD⁵, Gregory Cooper, MD⁶, Vu Q. Nguyen, MD, MS⁶, Jeffry Katz, MD⁶, Fabio Cominelli, MD, PhD⁶, Miguel D Regueiro, MD⁷, Emad Mansoor, MD^6
1University Hospitals Cleveland Medical Center, Cleveland, OH; ²University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; ³University Hospitals Clinical Research Center, Cleveland, OH; ⁴Banner - University of Arizona, Tucson, AZ; ⁵Medical College of Wisconsin, Milwaukee, WI; ⁶Digestive Health Institute, University Hospitals Cleveland Medical Center, Cleveland, OH; ⁷Cleveland Clinic, Cleveland, OH

Introduction: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is associated with many extraintestinal manifestations. While associated with other autoimmune and inflammatory disorders, there is scarce and conflicting data on the risk of myocarditis and pericarditis in IBD. We sought to evaluate the risk of myocarditis and pericarditis in IBD utilizing a large population-based database.

Methods: Using TriNetX, a de-identified database collecting real-time data on over 113 million patients, we performed a retrospective study identifying all adults (aged >18 years) with a diagnosis of CD (ICD-10: K50) and UC (ICD-10: K51) and with prescription of at least one IBD-specific medication or advanced therapy. Our control group included patients with irritable bowel syndrome (IBS) (a functional GI disorder). We used propensity score matching (PSM) to balance cohorts based on demographics, Charlson Comorbidity Index, and risk factors for myo- and pericarditis (Table 1). Patients with pre-existing cardiac conditions were excluded. We studied outcomes of the incidence of myocarditis and pericarditis in IBD and IBS. Odds ratios and 95% confidence intervals were reported and p-values < 0.05 were considered statistically significant.

Results: We identified 542,115 patients with IBS compared to 146,718 with IBD. Using propensity score matching, we identified a final cohort of 137,880 patients in each group. Overall myocarditis incidence was 0.02%. There was no difference in risk of myocarditis in the IBD cohort (n=12) compared to the IBS cohort (n=12). However, while overall pericarditis incidence was 0.67%, there was a slightly increased risk of pericarditis in patients with IBD (n=526) compared to those with IBS (n=401) (OR=1.313, 95% CI [1.153- 1.495], p< 0.05).

Discussion: In this large population-based study, we found no increased risk of myocarditis in patients with IBD compared to IBS. However, there was a slightly increased risk of pericarditis in IBD compared to IBS. This could be due to the differing inflammatory profiles, pathophysiologic mechanisms and treatment regimens found in IBD compared to IBS. Further prospective studies are needed to evaluate this association.



Disclosures:


Jenny Jan, MD¹, Jacques Halabi, MD², Elleson G. Harper, BS², Jaime A. Perez, PhD³, Kanwal Bains, MD⁴, Preetika Sinh, MD⁵, Gregory Cooper, MD⁶, Vu Q. Nguyen, MD, MS⁶, Jeffry Katz, MD⁶, Fabio Cominelli, MD, PhD⁶, Miguel D Regueiro, MD⁷, Emad Mansoor, MD⁶. P0968 - Risk of Myocarditis and Pericarditis in Patients With Inflammatory Bowel Disease: A Multi-Network Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.